FDA Continues Clinical Hold with Safety Concerns for Expanded Access Program

On October 15, 2019, the U.S. Food and Drug Administration (FDA) responded to MAPS with a continued clinical hold with safety concerns regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).